These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2245952)

  • 1. Digoxin-like immunoreactive substance and preterm labor.
    Ayhan A; Yarali H; Diker I; Urman B; Develioğlu O
    Gynecol Obstet Invest; 1990; 30(2):75-7. PubMed ID: 2245952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of tocolytic therapy on serum digoxin-like immunoreactive substance concentration.
    Yapar EG; Ayhan A
    Gynecol Obstet Invest; 1994; 37(1):10-3. PubMed ID: 8125400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum level of digoxin-like immunoreactive substances in newborn infants in the first two weeks of life, in umbilical cord blood and in pregnant patients at the time of labor].
    Gawaz MP; Schreiber R; Vogt W; Genz T; Kellner M
    Klin Padiatr; 1990; 202(1):31-6. PubMed ID: 2156105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of the presence of digoxin-like immunoreactive substance (DLIS) in the serum and urine in children with nephrotic syndrome.
    Shimabukuro N; Ebara H; Maruyama K; Tomizawa S; Kuroume T
    Clin Nephrol; 1988 May; 29(5):244-7. PubMed ID: 2840225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretion of atrial natriuretic peptide and digoxin-like immunoreactive substance during pregnancy.
    Shrivastav P; Gill DS; D'Souza V; O'Brien PM; Dandona P
    Clin Chem; 1988 May; 34(5):977-80. PubMed ID: 2967132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digoxin-like immunoreactive substance: monoclonal and polyclonal RIA and FPIA compared.
    Mojaverian P; Green PJ; Jhangiania RK; Chase GD
    J Pharm Biomed Anal; 1989; 7(5):585-92. PubMed ID: 2490762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary digoxin-like immunoreactive substance in pregnancy. Relation to urinary electrolytes.
    Friedman HS; Abramowitz I; Nguyen T; Babb B; Stern M; Farrer SM; Tricomi V
    Am J Med; 1987 Aug; 83(2):261-4. PubMed ID: 3618628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin-like immunoreactive substance in serum of preterm and full-term neonates.
    Bertrand JM; Langhendries JP; Gras A; Battisti O
    Eur J Pediatr; 1987 Mar; 146(2):145-6. PubMed ID: 3032639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference from digoxin-like immunoreactive substance(s) in commercial digoxin kit assay methods.
    Morris RG; Frewin DB; Saccoia NC; Goldsworthy WL; Jeffries WS; McPhee AJ
    Eur J Clin Pharmacol; 1990; 39(4):359-63. PubMed ID: 2076718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing analytical interferences from digoxin-like immunoreactive substances (DLIS) in cases of digoxin toxicity.
    Seccombe DW; Pudek MR; Humphries KH
    J Forensic Sci; 1987 May; 32(3):650-7. PubMed ID: 3598515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin-like immunoreactive substance (DLIS) in liver disease: comparison of clinical and laboratory parameters in patients with and without DLIS.
    Gervais A; Nanji AA; Greenway DC; McLean W
    Drug Intell Clin Pharm; 1987 May; 21(5):450-2. PubMed ID: 3582173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin-like immunoreactive substance in renal transplant patients.
    Schrader BJ; Maddux MS; Veremis SA; Mozes MF; Maturen A; Bauman JL
    J Clin Pharmacol; 1991 Dec; 31(12):1126-31. PubMed ID: 1662232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digoxin-like immunoreactive substance in renal failure: a reappraisal.
    Greenway DC; Nanji AA
    Nephron; 1986; 44(2):108-10. PubMed ID: 3774074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin-like immunoreactive substance in urine of patients with mucocutaneous lymph node syndrome (MCLS).
    Tamura H; Shimoyama S; Sunaga Y; Sakaguchi M; Kuroume T
    Angiology; 1992 Oct; 43(10):856-65. PubMed ID: 1335703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous digoxin-immunoreactive substance in normal and preeclamptic pregnancies.
    Loğoğlu G; Erdoğan S; Ozgünen FT; Doğan A; Ozgünen T; Kadayifçi O
    Int J Gynaecol Obstet; 1993 Nov; 43(2):137-43. PubMed ID: 7905428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of gestational age and preeclampsia on the presence and magnitude of serum endogenous digoxin-like immunoreactive substance(s).
    Phelps SJ; Cochran EB; Gonzalez-Ruiz A; Tolley EA; Hammond KD; Sibai BM
    Am J Obstet Gynecol; 1988 Jan; 158(1):34-9. PubMed ID: 3337179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstration of a relation between urinary digoxin-like immunoreactive substance and cardiac performance.
    Friedman HS; Babb B; Shim IB; Sotomora G; Farrer SM; Vasavada BC
    Chest; 1993 Mar; 103(3):878-81. PubMed ID: 8449085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal changes in a digoxin-like immunoreactive substance.
    Seccombe DW; Pudek MR; Whitfield MF; Jacobson BE; Wittmann BK; King JF
    Pediatr Res; 1984 Nov; 18(11):1097-9. PubMed ID: 6514436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digoxin-like substance in amniotic fluid--fact or artifact?
    Greenway DC; Nanji AA
    Gynecol Obstet Invest; 1986; 22(2):108-9. PubMed ID: 3770531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the carrier protein of digoxin-like immunoreactive substance in plasma.
    Montali U; Balzan S; Ghione S
    J Hypertens Suppl; 1987 Dec; 5(5):S299-302. PubMed ID: 3481818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.